Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)

PURPOSE: In this phase II response-adaptive trial, we investigated the rational application of immune checkpoint blockade in renal cell carcinoma (RCC; ClinicalTrials.gov identifier: NCT03203473). METHODS: We enrolled patients with metastatic RCC with no prior checkpoint inhibitor exposure. All pati...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Clin Oncol
Main Authors: McKay, Rana R., McGregor, Bradley A., Xie, Wanling, Braun, David A., Wei, Xiao, Kyriakopoulos, Christos E., Zakharia, Yousef, Maughan, Benjamin L., Rose, Tracy L., Stadler, Walter M., McDermott, David F., Harshman, Lauren C., Choueiri, Toni K.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Clinical Oncology 2020
Fag:
ORIGINAL REPORTS
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768333/
https://ncbi.nlm.nih.gov/pubmed/33108238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02295
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker